Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Goodwill (2016 - 2022)

Sangamo Therapeutics (SGMO) has disclosed Goodwill for 10 consecutive years, with $37.6 million as the latest value for Q4 2022.

  • For Q4 2022, Goodwill fell 5.42% year-over-year to $37.6 million; the TTM value through Dec 2022 reached $37.6 million, down 5.42%, while the annual FY2022 figure was $37.6 million, 5.42% down from the prior year.
  • Goodwill hit $37.6 million in Q4 2022 for Sangamo Therapeutics, up from $34.5 million in the prior quarter.
  • Across five years, Goodwill topped out at $42.8 million in Q4 2020 and bottomed at $1.6 million in Q1 2018.
  • Average Goodwill over 5 years is $33.7 million, with a median of $39.3 million recorded in 2019.
  • Year-over-year, Goodwill skyrocketed 2426.44% in 2018 and then fell 14.85% in 2022.
  • Sangamo Therapeutics' Goodwill stood at $40.0 million in 2018, then decreased by 1.93% to $39.3 million in 2019, then grew by 8.98% to $42.8 million in 2020, then fell by 7.23% to $39.7 million in 2021, then fell by 5.42% to $37.6 million in 2022.
  • According to Business Quant data, Goodwill over the past three periods came in at $37.6 million, $34.5 million, and $36.7 million for Q4 2022, Q3 2022, and Q2 2022 respectively.